DuPont Expands Bioprocessing Portfolio with Launch of DuPont™ AmberChrom™ TQ1 Chromatography Resin to Revolutionize Purification of Oligonucleotides and Peptides
DuPont Broadens, a global leader in innovative solutions for bioprocessing and life sciences, has announced the launch of its latest advancement in chromatography technology: the DuPont™ AmberChrom™ TQ1 chromatography resin. This new addition to DuPont’s bioprocessing portfolio is engineered to meet the increasing demand for efficient and scalable purification of oligonucleotides and peptides — critical biomolecules driving the next wave of therapeutic development across a wide spectrum of biopharmaceutical applications.
Addressing the Rising Demand for Oligonucleotide and Peptide Therapeutics
In recent years, DuPont Broadens oligonucleotide and peptide therapeutics have emerged as pivotal components in precision medicine and personalized therapies. These molecules offer highly specific mechanisms of action, enabling treatment of complex diseases including genetic disorders, cancers, and rare diseases. However, their complex structures and production processes require sophisticated purification methods to ensure safety, efficacy, and regulatory compliance.
Recognizing these challenges, DuPont has strategically expanded its bioprocessing solutions to empower biopharma companies with more robust and scalable technologies. The launch of DuPont™ AmberChrom™ TQ1 chromatography resin marks a significant milestone in this endeavor.
Exceptional Performance with Advanced Chromatography Resin Technology
Shane Kendra, Global Bioprocessing Market Leader at DuPont Water Solutions, emphasized the importance of this product launch:
“The introduction of DuPont™ AmberChrom™ TQ1 chromatography resin supports the accelerated development and commercialization of oligonucleotide and peptide therapeutics. In addition to expanding our capabilities, this new anion exchange chromatography resin offers exceptional performance, setting a new standard in this product class and creating new opportunities in high growth therapy areas.”
DuPont Broadens AmberChrom™ TQ1 is an agarose-based anion exchange resin meticulously engineered for high resolution and high-throughput purification tasks. One of its defining features is its superior loading capacity — meaning it can process a larger volume of biomolecule feedstock without compromising purity or yield. This improvement translates directly into greater process efficiency and cost savings for biomanufacturers.
Additionally, DuPont Broadens the resin operates with a lower pressure drop compared to comparable products in the market. Lower pressure requirements reduce the mechanical stress on chromatographic systems and allow for more flexible process scale-up — from benchtop R&D labs to full-scale commercial manufacturing.
Technical Benefits: High Throughput, Purity, and Scalability
The technical design of DuPont Broadens AmberChrom™ TQ1 enables several critical advantages for biopharmaceutical purification:
- Increased Loading Capacity: By accommodating more material per cycle, the resin accelerates throughput and reduces the number of required purification runs.
- Higher Resolution Separation: It excels at distinguishing closely related impurities from the target oligonucleotides or peptides, which is crucial for producing highly pure fractions essential for therapeutic applications.
- Low Pressure Build-Up: Reduced hydraulic pressure during operation not only protects equipment but also allows for seamless integration with existing chromatography systems.
- Versatile Purification: The resin is highly effective for both DMT-Off and DMT-On oligonucleotides as well as peptide feeds, supporting a wide range of process configurations from polishing steps to initial purification stages.
These DuPont Broadens properties make the AmberChrom™ TQ1 resin an ideal candidate for benchtop exploratory studies, pilot scale purification, and large-scale commercial manufacturing. It supports biopharma manufacturers throughout the drug development lifecycle, enabling consistent quality and scalable output.
Comprehensive Validation Through Real-World Application Studies
DuPont Broadens To substantiate the performance claims and aid users in process integration, DuPont conducted extensive internal application studies using authentic drug feedstocks. These studies simulate real-world production scenarios to validate the resin’s performance under practical conditions.
DuPont Broadens DuPont’s commitment to transparency and customer success is evident in its publication of these detailed application results, which serve as invaluable resources for process engineers and scientists designing purification workflows. These studies highlight AmberChrom™ TQ1’s capacity to consistently deliver high purity and yield, demonstrating its suitability from early discovery through to commercialization.
A One-Stop Shop for Oligonucleotide and Peptide Purification
DuPont Broadens DuPont’s expansion of its bioprocessing portfolio underscores its ambition to be a comprehensive, one-stop provider of purification and polishing technologies. As Shane Kendra noted:
“Further expansion of DuPont’s DuPont Broadens bioprocessing portfolio reflects our commitment to providing a comprehensive one-stop shop for the purification and polishing of oligonucleotides and peptides. Our technical teams and scientists are continually collaborating with customers to design efficient bioprocessing solutions for every stage of the drug development journey.”
DuPont Broadens offers a range of complementary AmberChrom™ chromatography resins, including AmberChrom™ XT and CG, that can be used in tandem with the new TQ1 resin to purify a broad spectrum of oligonucleotide feeds. This synergy enables optimized workflows for both crude purification of peptides and fine polishing steps, enhancing flexibility for diverse manufacturing processes.
Industry Launch and Knowledge Sharing at TIDES USA Conference
The debut of AmberChrom™ TQ1 chromatography resin was showcased at TIDES USA — a premier conference dedicated to accelerating innovation in oligonucleotide and peptide therapeutics.
At the event, Dr. Hadi Fares, a bioprocessing application scientist at DuPont, presented compelling application data demonstrating how AmberChrom™ TQ1 outperforms existing resins and complements DuPont’s established portfolio. These presentations helped industry professionals gain insights into practical deployment and benefits, fueling adoption and advancing the broader bioprocessing field.
Upcoming Educational Webinar to Support Adoption
Furthering its support for the biopharma community, DuPont announced an upcoming educational webinar scheduled for June 19, 2025. The webinar will focus on the capabilities of AmberChrom™ TQ1 chromatography resin, highlighting its loading capacity, purification efficiency, and practical tips for integration into existing processes.
This interactive session will provide bioprocess engineers, scientists, and production managers with the knowledge needed to leverage AmberChrom™ TQ1 effectively — accelerating timelines and enhancing therapeutic product quality.
Why AmberChrom™ TQ1 Matters for the Future of Biopharma
The launch of AmberChrom™ TQ1 chromatography resin is timely. The biopharma industry is rapidly evolving, with oligonucleotides and peptides becoming cornerstone molecules in the treatment of increasingly complex diseases. Efficient, scalable purification solutions are essential to translating laboratory discoveries into commercial realities.
AmberChrom™ TQ1’s combination of high loading capacity, superior resolution, and gentle operating conditions addresses these needs, empowering manufacturers to achieve higher productivity and consistent purity. Moreover, its compatibility with DuPont’s broader AmberChrom™ family of resins enables integrated, flexible purification platforms that can be tailored to specific drug candidates and process scales.
